The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback 
Novo Nordisk Strikes €1.17 Billion Nanexa Drug Delivery Deal 
Meta Connect Spotlights Camera-Free Smart Glasses Amid Privacy Concerns 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
Meta Unveils Muse Charm AI Device, Expands Smart Glasses Lineup 
FDA Weighs Safety Standards for Psychedelic Therapies 
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children 
SoftBank Raises $11.1 Billion in Bond Sale to Fund OpenAI Investment 
US 10-Year Treasury Yield at 6% Emerges as New Market Risk Threshold 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
SMBC Eyes 20% VPBank Stake in Vietnam Expansion 
Tencent Launches TenPayGo Payment App for Foreign Tourists in China 
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
Jeff Bezos Invests $32 Billion in Blue Origin as Space Firm Targets Major Growth 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Add as a preferred source on Google
Chinese biotech company Bliss Biopharmaceutical (BlissBio) is reportedly considering a Hong Kong initial public offering (IPO) that could raise at least $150 million, according to Bloomberg sources. The Hangzhou-based cancer drug developer is working with financial advisers to evaluate the listing, although final decisions have yet to be made and the IPO size could still change. There is also a possibility the company may postpone or cancel the plan.
Founded in 2017, BlissBio focuses on antibody-drug conjugates (ADCs) that specifically target tumors. The company currently has multiple therapies in early-stage clinical trials, including Phase 1 and Phase 2 studies, as stated on its website. ADCs are a cutting-edge treatment combining antibodies with cancer-killing agents to selectively target cancer cells, offering potential breakthroughs in oncology.
Investor interest in China's biotech sector remains strong, especially for innovative oncology firms. A recent example is Duality Biotherapeutics Inc (HK:9606), which saw its shares nearly double after its Hong Kong IPO last month, reflecting growing confidence in homegrown pharmaceutical innovation.
If successful, BlissBio’s IPO would join a wave of Chinese biotech listings on the Hong Kong Stock Exchange, which has become a favored venue for healthcare companies seeking capital to fund clinical trials and expand their R&D pipelines. With increasing demand for novel cancer therapies in China and globally, the market is watching closely to see whether BlissBio moves forward with the offering.
